When raising funds in the early stages of a business, founders often find themselves negotiating terms that feel foreign with angel investors, venture capital firms, accelerators, and incubators. Terms like equity, convertible notes, SAFEs, and “this is market” are thrown around casually, with pressure for the founder to trust the investor’s preferred form of instrument and proposed terms as the cost of doing business. Founders at this stage often don’t have an established relationship with a legal service provider who can provide guidance. But the reality is that these decisions are more than financial: providing an investor with an equity stake, or even with a convertible note or SAFE, carries ownership and governance ramifications that can shape founder control, investor relationships, future fundraising, eligibility for ownership-based certifications, and, for mission-driven companies, whether the business can protect its mission as it grows.
A founder who receives a SAFE or convertible note term sheet from a potential investor first needs to determine whether that instrument actually fits what the company and its investors are trying to accomplish. Both the SAFE and convertible note are forms of deferred-price financing: the investor provides capital now, but the parties postpone determining the investor’s ultimate equity ownership until a later financing or other specified event. As a result, these instruments tend to work best when a company needs funding to progress to the next level and expects to raise a priced equity round after reaching additional milestones, but the amount being raised, the difficulty of establishing a defensible valuation, or the time and expense of negotiating a priced round at the time makes issuing equity impractical.
The SAFE-versus-note decision commonly arises after the founders have concluded that grants or other non-dilutive funding will not meet the company’s needs; conventional debt is unavailable or poorly suited to a company without predictable cash flow; and a priced equity round is premature or disproportionately expensive. The company is instead raising enough capital from investors willing to accept early-stage risk to reach a meaningful next milestone—such as completing a product, demonstrating market traction, increasing revenue, or preparing for an institutional financing.
With that threshold in mind, this article compares SAFEs and convertible notes and then identifies the economic, ownership, and governance terms founders should evaluate regardless of which instrument they use. For mission-driven and ownership-certified companies, those terms can affect more than dilution; they can also affect control, eligibility, and the company’s ability to preserve its mission.
The Basics
Until SAFEs (Simple Agreement for Future Equity) were popularized in late 2013 by Y Combinator, a well-known startup accelerator, convertible notes were the most common form of early-stage investment instrument. A convertible note is a debt instrument that converts into equity under specified circumstances. Until conversion, it remains debt, typically with interest and a maturity date upon which an investor can demand repayment or that the note be converted into equity. Convertible notes give an investor creditor rights that equity does not, and a convertible note round can typically be negotiated at a lower cost than a priced equity round.
Since its introduction in 2013, the SAFE (Simple Agreement for Future Equity) has become widely used for early-stage and pre-seed startup financing. A SAFE is a contract that gives an investor the right to receive equity or, in certain circumstances, a cash payment upon events specified in the agreement. Because a SAFE is not a debt instrument, it does not create the same repayment pressure or creditor leverage as a note. It also generally uses shorter, more standardized documents and may therefore be faster and less expensive to negotiate than a convertible note round.
SAFE vs. Convertible Note: The Differences That Matter
Assuming a future-priced round is realistic, the choice of whether a SAFE or a convertible note is a better fit usually turns on whether the company values the SAFE’s simplicity and lack of repayment pressure or can accept (or the investor insists on) the interest, maturity, and creditor rights that come with debt. The principal differences are straightforward, but their practical effect depends on what happens after financing.
| Issue | SAFE | Convertible note |
| Legal structure | A contractual right to receive equity or payment upon specified events. | Debt until it converts or is repaid. |
| Interest | Generally, none. | Typically accrues and may convert with principal. |
| Maturity | Generally, none; it may remain outstanding for an extended period. | Has a maturity date that can require repayment, extension, or negotiated conversion. |
| Investor leverage | Limited to the rights in the SAFE and any side letter. | Includes creditor rights and may include covenants, security interests, or default remedies. |
| Priced round | Converts under the SAFE’s conversion formula. | Typically converts under the note’s formula, often including accrued interest. |
Those differences matter most if the expected priced round is delayed or never occurs. A SAFE generally does not create a repayment deadline, but it may remain outstanding indefinitely. A note creates a date by which the parties must address repayment, extension, or conversion, giving the investor leverage at a time when the company may have limited cash or financing options.
A SAFE may be the better fit when:
- A priced equity round is reasonably expected, but the company is not ready to price it today.
- The company wants to use shorter, relatively standardized documents and avoid accruing interest or negotiating a maturity date.
- The company understands that the SAFE may remain outstanding if the expected financing does not occur.
A convertible note may be the better fit when:
- The parties expect a financing or other milestone within a defined period and want a maturity date that will force a decision if it does not occur.
- The investor requires debt treatment, and the company is willing to accept accruing interest and creditor rights.
- The company can manage the consequences if the anticipated financing is delayed, and any covenants, security interests, or repayment rights will not unduly restrict operations or the next financing.
An investor’s preference for debt does not, by itself, make a convertible note the better choice for the company. Nor does the availability of a standardized SAFE make the SAFE inexpensive equity. The document identifies the legal structure; the negotiated terms and the company’s likely financing path determine the practical result.
Model What the Founders Are Selling
SAFEs and convertible notes often use a valuation cap, a discount on the price that the investor will pay for equity in the next round, or both. A valuation cap sets the maximum valuation used to calculate the conversion price. A discount reduces the next round’s share price for the early investor. If an instrument includes both, it generally converts using the method that produces the lower price—and therefore more shares—for the investor. A note may also convert accrued interest.
The valuation cap and discount help a founder understand how much of the company they are selling. For example, a $500,000 SAFE with a $5 million post-money valuation cap generally represents approximately 10% of the company immediately after the SAFE financing and before dilution from the priced round. A second SAFE, an option-pool increase, outstanding options or warrants, and the new money in the priced round can reduce the founders’ ownership further.
Whether the investment is structured as a SAFE or convertible note is one question. How the valuation cap and conversion economics are calculated is another. Pre-money and post-money terminology should therefore be analyzed after—not used to answer—the threshold question of which instrument fits the financing.
Before signing, give counsel or the company’s capitalization-table provider every outstanding SAFE, note, warrant, option, and promised equity grant. Ask for ownership models showing (1) the current capitalization, (2) conversion of all outstanding instruments, and (3) conversion plus the anticipated priced round and option-pool increase. If the next round’s size or valuation is uncertain, model more than one scenario.
Terms That Matter Regardless of the Instrument
Choosing a SAFE or convertible note does not resolve the entire financing. Founders should review the following terms in the context of the company’s existing documents, future financing plans, and relationships with the investor.
- Conversion and fallback. Identify the event that will cause the investment to convert and what happens if that event never occurs. The answer should cover automatic and optional conversion, repayment, extension, and any minimum financing threshold.
- Early exit or failure. Determine what the investor receives if the company is sold, goes public, or dissolves before conversion and where that payment sits in the priority waterfall.
- Investor rights and amendment mechanics. Review pro rata, most-favored-nation, information, consultation, consent, transfer, security, and covenant rights, along with who must approve amendments. Rights that seem modest in the first financing may become cumbersome after the company issues several instruments.
- Company-specific legal mechanics. Confirm the necessary corporate approvals and securities filings and review the tax and accounting treatment, the company’s governing documents, and any conflicts with existing investor rights or side letters.
Special Considerations for Mission-Driven and Certified Companies
For a company that holds or expects to seek WOSB, EDWOSB, MBE, WBE, DBE, 8(a), veteran-owned, or similar status, financing can affect eligibility before the instrument actually converts. Certification programs may consider conversion rights, board composition, investor vetoes, supermajority requirements, and other arrangements when deciding who owns and controls the business.
The federal WOSB rules, for example, generally require qualifying women to own at least 51% of each class of voting stock and 51% of the aggregate outstanding stock. Certain conversion rights held by nonqualifying investors may be treated as exercised, and investor rights that limit the qualifying owners’ control can create a separate problem. Because each program differs, counsel should review the actual financing terms under every certification regime that matters to the company—not simply confirm that a qualifying founder owns 51% of the shares outstanding today.
Mission-driven companies should apply the same discipline to investor alignment. Before accepting capital, discuss the investor’s time horizon, expected return, preferred exit, tolerance for sustainable rather than rapid growth, impact-measurement expectations, and likely response if the company misses its targets. A side letter cannot cure a fundamental mismatch on those questions.
Side letters can address matters such as impact reporting or use of proceeds, but durable mission protection usually belongs in the company’s governing documents and governance practices—for example, purpose provisions, benefit-corporation status where appropriate, board composition, or approval rights tailored to genuine mission changes. Those protections should be designed together with the financing terms so they do not create conflicting obligations, impede later fundraising, or inadvertently undermine an ownership or control certification.
Before You Sign
The founder’s questions fall into two groups: those that help determine whether a SAFE or convertible note better fits the company’s financing path, and those that should be answered in any early-stage financing.
Questions that help determine whether a SAFE or note fits:
- Financing path: Is a priced equity round or other conversion event realistically expected, and when?
- No next round: If that event does not occur, will the SAFE remain outstanding, will the note mature, or can either party force conversion, repayment, or an extension?
- Conversion economics: How do the valuation cap, discount, and, for a note, accrued interest interact?
- Debt consequences: Can the company accept the note’s maturity, creditor rights, covenants, security interests, and possible repayment obligation?
Questions to ask in any early-stage financing:
- Dilution: What will the founders, employees, and investors own after all instruments convert and after the expected priced round?
- Early exit or failure: What does the investor receive if the company is sold or dissolved before conversion, and where does that payment sit in the priority waterfall?
- Ownership, control, and mission: Could conversion or investor rights affect a certification, license, grant, customer commitment, or the company’s ability to pursue its mission?
- Legal mechanics: Have the company-specific approvals, securities filings, tax and accounting treatment, amendment provisions, and conflicts with existing documents been reviewed?
The Bottom Line
Choosing between a SAFE and convertible note is only one part of structuring an early-stage financing. Founders should begin by asking whether a deferred-price instrument fits the company’s actual financing path. If a priced round is reasonably expected, a SAFE may be the more natural choice when the company wants a shorter, simpler financing without interest or maturity pressure. A convertible note may fit when the parties want debt economics and a defined deadline, and the company can accept the leverage and repayment risk that come with them. If no priced round or other realistic conversion event is anticipated, the better answer may be neither.
Whatever instrument the company uses, the founders should model the economics and test the terms against the ownership, control, certification, and mission commitments that matter to the business. A readily available template is a starting point—not a substitute for that analysis.
Author
-
Heather Pruger is an experienced corporate and transactional attorney with extensive experience helping high-growth, technology-driven businesses navigate growth, complexity, and change. She works closely with founders, executives, boards, and in-house teams through acquisitions, investments, legal function buildout, and leadership transitions.


